Stoke Therapeutics shares are trading lower after the company announced new safety and efficacy data from STK-001 in the two ongoing Phase 1/2a studies and the SWALLOWTAIL open-label extension study in children and adolescents with Dravet syndrome.
Portfolio Pulse from Benzinga Newsdesk
Stoke Therapeutics announced new safety and efficacy data from STK-001 in the two ongoing Phase 1/2a studies and the SWALLOWTAIL open-label extension study in children and adolescents with Dravet syndrome. This news led to a decrease in the company's share price.
July 25, 2023 | 4:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Stoke Therapeutics' shares are trading lower after the company announced new safety and efficacy data from ongoing studies.
The announcement of new safety and efficacy data from Stoke Therapeutics' ongoing studies has led to a decrease in the company's share price. This suggests that the market may have had negative perceptions of the data, leading to a sell-off of the company's shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100